Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

September 27, 2017

By Manali Kamdar, MD The presentation and course of CLL is strikingly varied in patients, with some individuals presenting with a biologically indolent course whereas others present with an aggressive course. Hence, it is imperative to get information about individual patient prognosis in order to define a therapeutic strategy
Ibrutinib (eye-broo-ti-nib), which is marketed under the tradename of Imbruvica® in the U.S. and Canada, is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK). Upon oral administration, ibrutinib binds to and irreversibly inhibits the activity of BTK which prevents both B-cell activation and B-cell-mediated signaling. This action leads
By Dr. La Verne Abe Harris – Patient Dear Caregivers: When I was diagnosed with cancer, my focus was on my health and finding a way of getting better and improving my chances of survival. It was not until I attended a cancer support group and a caregiver gave